Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ · Healthcare
$33.50-0.80%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $2.13B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,045,934
- 52-week high
- —
- 52-week low
- —
- Open
- $33.97
- Day high
- $34.27
- Day low
- $33.34
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $868.45M | $158.69M | $2.71 |
| 2024 | $714.73M | $145.49M | $2.51 |
| 2023 | $582.02M | $128.85M | $2.13 |
| 2022 | $437.86M | $181.47M | $2.97 |
| 2021 | $305.44M | $34.6M | $0.58 |
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
- CEO
- Jeffrey Dayno
- Employees
- 268
- Country
- US
- IPO date
- Aug 19, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Harmony Biosciences Holdings, Inc.'s stock price today?
- HRMY is trading at $33.50 as of Jul 20, 2026.
- What is Harmony Biosciences Holdings, Inc.'s market cap?
- Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.13B.
- Does Harmony Biosciences Holdings, Inc. pay a dividend?
- Harmony Biosciences Holdings, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Harmony Biosciences Holdings, Inc. in?
- Harmony Biosciences Holdings, Inc. operates in the Healthcare sector.